Critical Comparison: Innovus Pharmaceuticals (INNV) & Its Competitors

Innovus Pharmaceuticals (OTCMKTS: INNV) is one of 485 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Innovus Pharmaceuticals to related businesses based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, earnings and profitability.

Risk and Volatility

How to Become a New Pot Stock Millionaire

Innovus Pharmaceuticals has a beta of 3.96, suggesting that its stock price is 296% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals’ rivals have a beta of 1.08, suggesting that their average stock price is 8% more volatile than the S&P 500.

Institutional and Insider Ownership

47.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 19.1% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 15.2% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Innovus Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -73.78% -299.94% -62.83%
Innovus Pharmaceuticals Competitors -3,093.91% -156.11% -27.25%

Valuation and Earnings

This table compares Innovus Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innovus Pharmaceuticals $8.82 million -$6.50 million -3.63
Innovus Pharmaceuticals Competitors $2.03 billion $132.98 million -3.54

Innovus Pharmaceuticals’ rivals have higher revenue and earnings than Innovus Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Innovus Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Innovus Pharmaceuticals Competitors 2762 8507 21327 569 2.59

As a group, “Pharmaceutical preparations” companies have a potential upside of 42.35%. Given Innovus Pharmaceuticals’ rivals higher probable upside, analysts plainly believe Innovus Pharmaceuticals has less favorable growth aspects than its rivals.

Summary

Innovus Pharmaceuticals rivals beat Innovus Pharmaceuticals on 6 of the 9 factors compared.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company's pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply